WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)

相似書籍

• WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
  由: Radko Komers, et al.
  出版: (2024-04-01)
• Sparsentan Versus Irbesartan in Pediatric Patients With FSGS
  由: Michelle N. Rheault, et al.
  出版: (2026-07-01)
• Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
  由: Kirk N. Campbell, et al.
  出版: (2024-06-01)
• Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS
  由: Georgina Gyarmati, et al.
  出版: (2024-10-01)
• WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
  由: Chee Kay Cheung, et al.
  出版: (2024-04-01)